The importance of time in therapeutic range of warfarin for stroke prevention in atrial fibrillation.

[1]  R. Krittayaphong,et al.  Impact of Achieving Blood Pressure Targets and High Time in Therapeutic Range on Clinical Outcomes in Patients With Atrial Fibrillation Adherent to the Atrial Fibrillation Better Care Pathway: A Report From the COOL‐AF Registry , 2023, Journal of the American Heart Association.

[2]  Tuncay Güzel,et al.  Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and NOACs: Insight from AFTER-2 Trial. , 2023, Kardiologia polska.

[3]  T. Chao,et al.  2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary , 2021, Thrombosis and Haemostasis.

[4]  T. Chao,et al.  2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation , 2021, Journal of arrhythmia.

[5]  T. Chao,et al.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Clinical Outcomes in Asian Patients with Atrial Fibrillation. , 2020, Heart rhythm.

[6]  T. Chao,et al.  Should We Adopt a Standard International Normalized Ratio Range of 2.0 to 3.0 for Asian Patients with Atrial Fibrillation? An Appeal for Evidence-Based Management, Not Eminence-Based Recommendations , 2020, Thrombosis and Haemostasis.

[7]  T. Chao,et al.  Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. , 2018, Circulation.

[8]  N. Stockbridge,et al.  Relationship between International Normalized Ratio and Outcomes in Modern Trials with Warfarin Controls , 2018, Pharmacotherapy.

[9]  T. Chao,et al.  Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study , 2017, Chest.

[10]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[11]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[12]  J. Plumb,et al.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[13]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.